Articles from Orvida Pharma Ltd

Orvida Pharma (formerly Kamari Pharma) Announces Favorable Phase 1a Safety Data for KM-023, a Potential First-in-Disease Oral TRPV3 Inhibitor, and Initiation of Phase 1b Study in Patients with Olmsted Syndrome
First Olmsted syndrome patient dosed in global Phase 1b study
By Orvida Pharma Ltd · Via GlobeNewswire · April 15, 2026